Commentary Commentaire about 12.7 years. 8 Because persistent infection with highrisk
HPV is necessary for the development of CIN, the mean time between initial infection and …

Cervical cancer is the second most common cancer in women worldwide and the seventh
most common cause of cancer deaths in women in Europe. Today, we know how to prevent …

Within the past 5 years, guidelines recognizing the value of HPV testing in both primary
cervical screening and in the management of abnormal cervical cytology have been …

Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug
Administration for use as an adjunct to cytology for cervical cancer screening. To help …

Although cytology-based cervical cancer prevention programs have reduced the incidence
of cervical cancer in many industrialized countries, the limited sensitivity of cervical cytology …

What was not fully appreciated until recently was the fact that although the case was being
made for using both tests in parallel for enhanced detection of cervical precancers, the …

Traditional population-based cervical screening programs, based on cytology, have
successfully reduced the burden of cervical cancer. Nevertheless limitations remain and …

Over the past 25 years, not only have “high-risk” human papillomaviruses (HPVs) been
identified as the causal agents of cervical cancer, but also accurate clinical assays have …

Introduction: High-risk human papillomavirus (hrHPV) testing is expected to replace cytology
as primary screening method for cervical cancer screening in an increasing number of …

Strong evidence now supports the adoption of cervical cancer prevention strategies that
explicitly focus on persistent infection with the causal agent, human papillomavirus (HPV) …